Mark James Litton Athira Pharma, Inc. (ATHA) insider trading activity

Mark James Litton is President and CEO of Athira Pharma, Inc.. Currently has a direct ownership of 325,802 shares of ATHA, which is worth approximately $97,740. The most recent transaction as insider was on Jul 01, 2025, when has been sold 25,123 shares (Common Stock) at a price of $0.29 per share, resulting in proceeds of $7,285. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 326K

34.3% 3M change

125.63% 12M change

Total Value Held $97,740

Mark James Litton Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 01 2025	SELL Open market or private sale	$7,285 $0.29 p/Share	25,123 Reduced 7.16%	325,802 Common Stock
Jun 30 2025	BUY Exercise of conversion of derivative security	-	108,334 Added 23.59%	350,925 Common Stock
Jan 02 2025	SELL Open market or private sale	$14,059 $0.56 p/Share	25,107 Reduced 9.38%	242,591 Common Stock
Dec 31 2024	BUY Exercise of conversion of derivative security	-	108,333 Added 28.81%	267,698 Common Stock
Sep 05 2024	SELL Open market or private sale	$2,868 $0.57 p/Share	5,032 Reduced 3.06%	159,365 Common Stock
Sep 03 2024	BUY Grant, award, or other acquisition	-	20,000 Added 10.85%	164,397 Common Stock
Jan 05 2024	SELL Open market or private sale	$14,026 $2.91 p/Share	4,820 Reduced 3.23%	144,397 Common Stock
Jan 04 2024	BUY Grant, award, or other acquisition	-	20,000 Added 11.82%	149,217 Common Stock
Nov 18 2022	BUY Grant, award, or other acquisition	$1,813 $2.74 p/Share	662 Added 0.51%	129,217 Common Stock
Jun 23 2022	SELL Open market or private sale	$21,412 $2.69 p/Share	7,960 Reduced 5.83%	128,555 Common Stock
Jun 22 2022	BUY Grant, award, or other acquisition	-	20,000 Added 12.78%	136,515 Common Stock
May 18 2022	BUY Grant, award, or other acquisition	$5,344 $7.06 p/Share	757 Added 0.65%	116,515 Common Stock
Nov 18 2021	BUY Grant, award, or other acquisition	$11,071 $12.51 p/Share	885 Added 0.76%	115,758 Common Stock
Aug 17 2021	BUY Exercise of conversion of derivative security	$68,094 $1.35 p/Share	50,440 Added 30.51%	114,873 Common Stock
May 18 2021	BUY Grant, award, or other acquisition	$12,528 $14.45 p/Share	867 Added 1.33%	64,433 Common Stock

MJL

Mark James Litton

President and CEO

Bothell, WA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ATHA shares.

Notify only if

Value

Insider Trading

Get notified when an Athira Pharma, Inc. insider buys or sells ATHA shares.

Notify only if

Operation

Value

Type

News

Receive news related to Athira Pharma, Inc.

Track Activities on ATHA

Account